Dynamic PET and optical imaging and compartment modeling using a Dual-labeled cyclic RGD peptide probe

Theranostics

Volumn 2, Issue 8, 2012, Pages 746-756

  Zhu, Lei ^a,b   Guo, Ning ^b,c   Li, Quanzheng ^d   Ma, Ying ^b   Jacboson, Orit ^b   Lee, Seulki ^b   Choi, Hak Soo ^e   Mansfield, James R ^f   Niu, Gang ^b   Chen, Xiaoyuan ^b  

^a XIAMEN UNIVERSITY   (China)

^b NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING   (United States)

^c HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^f Caliper Life Sciences   (United States)

Author keywords

Dual modality imaging; Dynamic imaging; integrin v 3; Kinetic modeling; RGD peptide; Singular value decompo sition (SVD)

Indexed keywords

ARGINYLGLYCYLASPARTIC ACID; COPPER 64; TETRAXETAN; VITRONECTIN RECEPTOR;

ACCURACY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BINDING KINETICS; CANCER MODEL; COMPARTMENT MODEL; CONJUGATION; CONTROLLED STUDY; FEMALE; IC 50; IMAGE ANALYSIS; IMAGING SYSTEM; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; MOUSE; NONHUMAN; OPTICAL IMAGING; PEPTIDE SYNTHESIS; POSITRON EMISSION TOMOGRAPHY; PROTEIN BINDING; QUANTITATIVE ANALYSIS; RECEPTOR BINDING; SIGNAL PROCESSING;

EID: 84866015073     PISSN: None     EISSN: 18387640     Source Type: Journal    
DOI: 10.7150/thno.4762     Document Type: Article

References (41)

1. Cai W, Rao J, Gambhir SS, Chen X. How molecular imaging is speeding up antiangiogenic drug development. Mol Cancer Ther. 2006; 5: 2624-33.
2. Delbeke D. Oncological applications of FDG PET imaging: Brain tumors, colorectal cancer, lymphoma and melanoma. J Nucl Med. 1999; 40: 591-603.
3. Bomanji JB, Costa DC, Ell PJ. Clinical role of positron emission tomography in oncology. Lancet Oncol. 2001; 2: 157-64.
4. La Fougere C, Suchorska B, Bartenstein P, Kreth FW, Tonn JC. Molecular imaging of gliomas with PET: Opportunities and limitations. Neuro Oncol. 2011;13: 806-19.
5. Phelps ME. PET: The merging of biology and imaging into molecular imaging. J Nucl Med. 2000; 41: 661-81.
6. Cai W, Chen X. Multimodality molecular imaging of tumor angiogenesis. J Nucl Med. 2008; 49 Suppl 2: 113S-28S.
7. Ye Y, Chen X. Integrin targeting for tumor optical imaging. Theranostics. 2011;1: 102-26.
8. Hoshi Y. Functional near-infrared optical imaging: Utility and limitations in human brain mapping. Psychophysiology. 2003; 40: 511-20.
9. Shah K, Weissleder R. Molecular optical imaging: Applications leading to the development of present day therapeutics. NeuroRx. 2005; 2: 215-25.
10. Ntziachristos V, Bremer C, Weissleder R. Fluorescence imaging with near-infrared light: New technological advances that enable in vivo molecular imaging. Eur Radiol. 2003; 13: 195-208.
11. Zhu L, Niu G, Fang X, Chen X. Preclinical molecular imaging of tumor angiogenesis. Q J Nucl Med Mol Imaging. 2010;54: 291-308.
12. Niu G, Chen X. Why integrin as a primary target for imaging and therapy. Theranostics. 2011; 1: 30-47.
13. Carter A. Integrins as target: First phase III trial launches, but questions remain. J Natl Cancer Inst. 2010;102: 675-7.
14. Millard M, Odde S, Neamati N. Integrin Targeted Therapeutics. Theranostics 2011; 1: 154-188.
15. Schottelius M, Laufer B, Kessler H, Wester HJ. Ligands for mapping αvβ3-integrin expression in vivo. Acc Chem Res. 2009; 42: 969-80.
16. Lee HY, Li Z, Chen K, Hsu AR, Xu C, Xie J, et al. PET/MRI dual-modality tumor imaging using arginine-glycine-aspartic (RGD)-conjugated radiolabeled iron oxide nanoparticles. J Nucl Med. 2008; 49: 1371-9.
17. Cai W, Chen K, Li ZB, Gambhir SS, Chen X. Dual-function probe for PET and near-infrared fluorescence imaging of tumor vasculature. J Nucl Med. 2007; 48: 1862-70.
18. Yang M, Gao H, Sun X, Yan Y, Quan Q, Zhang W, et al. Multiplexed PET probes for imaging breast cancer early response to VEGF/rGel treatment. Mol Pharm. 2011; 8: 621-8.
19. Shoghi KI. Quantitative small animal PET. Q J Nucl Med Mol Imaging. 2009; 53: 365-73.
20. Zhou H, Luby-Phelps K, Mickey BE, Habib AA, Mason RP, Zhao D. Dynamic near-infrared optical imaging of 2-deoxyglucose uptake by intracranial glioma of athymic mice. PLoS One. 2009; 4: e8051.
21. Keereweer S, Kerrebijn JD, Van Driel PB, Xie B, Kaijzel EL, Snoeks TJ, et al. Optical image-guided surgery--where do we stand? Mol Imaging Biol. 2011; 13: 199-207.
22. Robinson MR, Hutchinson MD. Use of imaging techniques to guide catheter ablation procedures. Curr Cardiol Rep. 2010; 12: 374-81.
23. Hong YT, Beech JS, Smith R, Baron JC, Fryer TD. Parametric mapping of [18F]fluoromisonidazole positron emission tomography using basis functions. J Cereb Blood Flow Metab. 2011;31: 648-57.
24. Gurfinkel M, Ke S, Wang W, Li C, Sevick-Muraca EM. Quantifying molecular specificity of αvβ3 integrin-targeted optical contrast agents with dynamic optical imaging. J Biomed Opt. 2005; 10: 034019.
25. Ferl GZ, Dumont RA, Hildebrandt IJ, Armijo A, Haubner R, Reischl G, et al. Derivation of a compartmental model for quantifying 64Cu-DOTA-RGD kinetics in tumor-bearing mice. J Nucl Med. 2009; 50: 250-8.
26. Logan J. A review of graphical methods for tracer studies and strategies to reduce bias. Nucl Med Biol. 2003; 30: 833-44.
27. Logan J, Fowler JS, Volkow ND, Wang GJ, Ding YS, Alexoff DL. Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab. 1996; 16: 834-40.
28. Logan J, Fowler JS, Volkow ND, Wolf AP, Dewey SL, Schlyer DJ, et al. Graphical analysis of reversible radioligand binding from time-activity measurements applied to [n-11c-methyl]-(-)-cocaine PET studies in human subjects. J Cereb Blood Flow Metab. 1990; 10: 740-7.
29. Hillman EM, Moore A. All-optical anatomical co-registration for molecular imaging of small animals using dynamic contrast. Nat Photonics. 2007; 1: 526-30.
30. Lawson CL, Hanson RJ. Solving least squares problems. Philadelphia: SIAM. 1995.
31. Miller K. Least squares methods for ill-posed problems with a prescribed bound. SIAM J Math Anal. 1970; 1: 52-74.
32. Li ZB, Cai W, Cao Q, Chen K, Wu Z, He L, et al. 64Cu-labeled tetrameric and octameric RGD peptides for small-animal PET of tumor αvβ3 integrin expression. J Nucl Med. 2007; 48: 1162-71.
33. Sun X, Yan Y, Liu S, Cao Q, Yang M, Neamati N, et al. 18F-FPPRGD2 and 18F-FDG PET of response to abraxane therapy. J Nucl Med. 2011;52: 140-6.
34. Zhang X, Xiong Z, Wu Y, Cai W, Tseng JR, Gambhir SS, et al. Quantitative PET imaging of tumor integrin αvβ3 expression with 18F-FRGD2. J Nucl Med. 2006; 47: 113-21.
35. Godavarty A, Thompson AB, Roy R, Gurfinkel M, Eppstein MJ, Zhang C, et al. Diagnostic imaging of breast cancer using fluorescence-enhanced optical tomography: Phantom studies. J Biomed Opt. 2004; 9: 488-96.
36. Solomon M, White BR, Nothdruft RE, Akers W, Sudlow G, Eggebrecht AT, et al. Video-rate fluorescence diffuse optical tomography for in vivo sentinel lymph node imaging. Biomed Opt Express. 2012; 2: 3267-77.
37. Beer AJ, Haubner R, Goebel M, Luderschmidt S, Spilker ME, Wester HJ, et al. Biodistribution and pharmacokinetics of the αvβ3-selective tracer 18F-galacto-RGD in cancer patients. J Nucl Med. 2005; 46: 1333-41.
38. Choi HS, Nasr K, Alyabyev S, Feith D, Lee JH, Kim SH, et al. Synthesis and in vivo fate of zwitterionic near-infrared fluorophores. Angew Chem Int Ed Engl. 2011;50: 6258-63.
39. Chen X, Conti PS, Moats RA. In vivo near-infrared fluorescence imaging of integrin αvβ3 in brain tumor xenografts. Cancer Res. 2004; 64: 8009-14.
40. Haubner R, Wester HJ, Weber WA, Mang C, Ziegler SI, Goodman SL, et al. Noninvasive imaging of αvβ3 integrin expression using 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res. 2001; 61: 1781-5.
41. Guo N, Lang L, Gao H, Niu G, Kieswetter D, Xie Q, et al. Quantitative analysis and parametric imaging of 18F-labeled monomeric and dimeric RGD peptides using a three-compartment model. Mol Imaging Biol.[Epub ahead of print] 2012;.